Nonmedical use of prescription drugs in the European Union

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Novak, Scott P ^a   Håkansson, Anders ^b,f   Martinez Raga, Jose ^c   Reimer, Jens ^d   Krotki, Karol ^a   Varughese, Sajan ^e  

^a RTI INTERNATIONAL   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e SHIRE   (United States)

^f LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; ILLICIT DRUG; OPIATE; PRESCRIPTION DRUG; SEDATIVE AGENT; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; DENMARK; EUROPEAN UNION; FEMALE; GERMANY; GREAT BRITAIN; HUMAN; MALE; MENTAL HEALTH; NONMEDICAL PRESCRIPTION DRUG USE; OFF LABEL DRUG USE; PREVALENCE; RISK FACTOR; SCHOOL CHILD; SELF CARE; SEXUAL HEALTH; SPAIN; SWEDEN; WORLD HEALTH ORGANIZATION; SUBSTANCE-RELATED DISORDERS; UNITED KINGDOM; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-SECTIONAL STUDIES; DENMARK; EUROPEAN UNION; FEMALE; GERMANY; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PRESCRIPTION DRUGS; PREVALENCE; RISK FACTORS; SPAIN; SUBSTANCE-RELATED DISORDERS; SWEDEN; UNITED KINGDOM; YOUNG ADULT;

EID: 84984854025     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-0909-3     Document Type: Article

References (50)

1. Boyd CJ, McCabe SE. Coming to terms with the nonmedical use of prescription medications. Subst Abuse Treat Prev Policy. 2008;3:22.
2. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-74.
3. Manchikanti L, Helm 2nd S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9-38.
4. ONDCP. Epidemic: Responding to America's prescription drug abuse epidemic. 2012. http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf. Accessed 15 Jan 2015.
5. Time. Why America can't kick its pain reliever problem. 2015. http://time.com/3908648/why-america-cant-kick-its-painkiller-problem/. Accessed 25 Jun 2015.
6. Zuvekas SH, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry. 2012;169(2):160-6.
7. Sites BD, Beach ML, Davis MA. Increases in the use of prescription opioid analgesics and the lack of improvement in disability metrics among users. Reg Anesth Pain Med. 2014;39(1):6-12.
8. International Narcotic Control Board. Narcotic drugs technical report: Estimated world requirements for 2013 - statistics for 2011 (No. T.13.XI.2). New York: International Narcotics Control Board; 2013.
9. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol. 2009;24(4):211-6.
10. Moustgaard H, Joutsenniemi K, Myrskyla M, Martikainen P. Antidepressant sales and the risk for alcohol-related and non-alcohol-related suicide in Finland--an individual-level population study. PLoS One. 2014;9(6), e98405.
11. Ramaekers JG, Kuypers KP, Samyn N. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction. 2006;101(11):1614-21.
12. Mains KB. Prescription drug abuse rises globally. JAMA. 2007;297(12):1306.
13. SAMHSA. Results from the 2013 National Survey on drug use and Health: Summary of National Findings. Rockville: Substance Abuse and Mental Health Services Administration; 2014.
14. SAMHSA. Treatment Episode Data Set (TEDS): 2001-2011. State admissions to substance abuse treatment services. Rockville: Substance Abuse and Mental Health Services Administration; 2012.
15. Wu CL, Agarwal S, Tella PK, et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology. 2008;109(2):289-96.
16. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System (BRFSS). 2013. http://www.cdc.gov/brfss/ Accessed 17 Feb 2013.
17. Centers for Disease Control and Prevention. National Vital Statistics System: Mortality Data. 2015. http://www.cdc.gov/nchs/deaths.htm. Accessed 3 Aug 2015.
18. RTI. Legalized marijuana in the United States: resulting policy implications. 2015. https://www.youtube.com/watch?v=L-TpPPXxC4E. Accessed 23 May 2015.
19. Drug Enforcement Agency. National forensic laboratory information system: midyear report 2014. Springfield: US Drug Enforcement Agency; 2015.
20. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national results on drug use: key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2013.
21. European Monitoring Centre for Drugs and Drug Abuse. Data Tables. 2015. http://www.emcdda.europa.eu/stats13display:/stats13/gpstab1c. Accessed 24 Mar 2015.
22. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-8.
23. Katz NDR, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205-17.
24. Musto D. Iatrogenic addiction: The problem, its definition, and history. Bull NY Acad Med. 1985;61(8):694-9.
25. Weissman DE, Haddox JD. Opioid pseudoaddiction--an iatrogenic syndrome. Pain. 1989;36(3):363-6.
26. Wright ER, Kooreman HE, Greene MS, Chambers RA, Banerjee A, Wilson J. The iatrogenic epidemic of prescription drug abuse: county-level determinants of opioid availability and abuse. Drug Alcohol Depen. 2014;138:209-15.
27. EURAD. Alarming rates of prescription drug abuse in the EU. http://www.eurad.net/en/news/consumption_data/Alarming+Prescription+Drug+Abuse.9UFRnM1Q.ips. Accessed 20 Nov 2015.
28. Bachhuber MA, Cunningham CO. Availability of buprenorphine on the Internet for purchase without a prescription. Drug Alcohol Depen. 2013;130(1-3):238-40.
29. De Paoli G, Brandt SD, Pounder DJ. Mephedrone. Banned but still available on the internet. BMJ. 2011;342:d1629.
30. Inciardi JASH, Cicero TJ, et al. Prescription drugs purchased through the internet: who are the end users? Drug Alcohol Depen. 2010;110(1-2):21-9.
31. Moser C, Stuart A. An experimental study of quota sampling. J Royal Stat Soc. 1953;116(4):349-505.
32. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007;2:32.
33. Cochran W. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313.
34. Finkel JC, Elrefai A. The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesth Analg. 2004;98(6):1658-9.
35. Aldworth J, Colpe LJ, Gfroerer JC, et al. The National survey on drug use and health mental health surveillance study: calibration analysis. Int J Methods Psychiatric Res. 2010;19 Suppl 1:61-87.
36. SAMHSA. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville: Substance Abuse and Mental Health Services Administration; 2013.
37. Bohnert ASVM, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-21.
38. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-92.
39. Hall AJLJ, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-20.
40. Hickman M, Carrivick S, Paterson S, et al. London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. Addiction. 2007;102(2):317-23.
41. Boyd CJ, Teter CJ, West BT, Morales M, McCabe SE. Non-medical use of prescription analgesics: a three-year national longitudinal study. J Addict Dis. 2009;28(3):232-42.
42. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269-78.
43. Jena AB. Growing Internet use may help explain the rise in prescription drug abuse in the United States. Health Aff. 2011;30(6):1192-9.
44. Pew. Internet and American Life Project. 2009. http://www.pewinternet.org/Reports/2009/Generations-Online-in-2009.aspx. Accessed 20 Nov 2015.
45. Eurostat. Internet usage among EU adults. 2015. https://ec.europa.eu/digital-agenda/en/news/internet-usage-individuals-2014. Accessed 21 Jun 2015.
46. Musshoff F, Hottmann L, Hess C, Madea B. "Legal highs" from the German internet--"bath salt drugs" on the rise. Arch Kriminol. 2013;232(3-4):91-103.
47. Sare J. How the media helped ban mephedrone. BMJ. 2011;342:d1138.
48. Spijkerman R, Knibbe R, Knoops K, Van De Mheen D, Van Den Eijnden R. The utility of online panel surveys versus computer-assisted nterviews in obtaining substance-use prevalence estimates in the Netherlands. Addiction. 2009;104(10):1641-5.
49. Richter L, Johnson PB. Current methods of assessing substance use: a review of strengths, problems, and developments. J Drug Issues. 2001;31:809-32.
50. European Monitoring Center for Drugs and Drug Abuse. Table GPS-0. Nationwide surveys among the general population: bibliographic references. http://www.emcdda.europa.eu/stats13/gpstab0. Accessed 21 July 2015.